Kimon Doukoumetzidis

Kimon began his career in biomedical research nearly 20 years ago before transitioning into the pharmaceutical industry, where he has spent the last 11 years at Novartis. During this time, he has held roles of increasing responsibility in both medical affairs and commercial functions at the country, cluster, regional, and global levels. He has been instrumental in the successful launch of numerous innovative drugs across various therapeutic areas. This includes two pioneering gene therapies that have marked significant advancements in medical history and several projects that leverage artificial intelligence to accelerate the diagnosis of patients with rare diseases.

Currently, as the Global Head of Medical Diagnostics, Kimon leads initiatives to promote early and accurate diagnosis for patients suffering from Spinal Muscular Atrophy (SMA), Inherited Retinal Dystrophies (IRD), and autoinflammatory diseases worldwide. He is also dedicated to developing innovative solutions that shorten the time from diagnosis to treatment, aiming to improve patient outcomes globally. Beyond his contributions to the pharmaceutical and biomedical research fields, Kimon regularly serves as a judge in venture competitions and hackathons and has mentored and advised numerous startups leveraging his extensive expertise to promote innovation and entrepreneurship within the healthcare sector.

Kimon holds a degree in Molecular and Cellular Biochemistry from the University of Paris, a doctorate in Molecular Genetics from the University of Zurich, and an MBA from the Massachusetts Institute of Technology Sloan School of Management.